Don’t forget you can visit MyAlerts to manage your alerts at any time.
By Adolfo Pesquera | January 11, 2024
The disagreement stems from a section of the licensing agreement stating in paragraph two the royalty rate will not exceed a half-percent for products that "detect Lyme disease in combination with one other veterinary diagnostic test," but paragraph three states a royalty rate of 2.5% for products that "detect Lyme disease in combination with one or more veterinary diagnostic products."
4 minute read
By ALM Staff | January 2, 2024
"Be good at what you do and take the time to make sure others know that you are good at what you do."
7 minute read
By Jennifer Bush | December 22, 2023
Perhaps the largest impact that Director Vidal has had upon the PTAB is has been via Director Reviews. The U.S. Supreme Court mandated Director Reviews to correct procedural defects in the way that administrative patent judges are appointed to the PTAB.
11 minute read
By Alex Anteau | December 15, 2023
Experts say the move will increase client confidence as more Fortune 500 companies set up shop in Georgia.
3 minute read
By Marisa Rauchway and Joseph V. Saphia | December 12, 2023
Manufacturers, distributors, patent holders, consultants, retailers and others similarly situated often find themselves in business relationships that may trigger the broad reach of franchise laws. Indeed, those businesses who operate in New York would be wise to be particularly careful in light of New York's exceptionally broad statutory language.
6 minute read
By James W. Soong | November 29, 2023
Recent developments at the Federal Circuit and the USPTO may inform evolving patent strategy on medical technology.
11 minute read
By Adolfo Pesquera | November 27, 2023
"Samsung's resounding victory not only safeguards its current market position but also sets a powerful precedent in the ever-evolving landscape of patent litigation," the Quinn Emanuel team stated.
3 minute read
By Philip L. Hirschhorn and Ikenna C. Ejimonyeugwo | November 22, 2023
The quandary is whether an AI platform that assists in creating an invention should be named as an inventor in a patent. For example, an AI-powered system may be employed pharmaceutically to identify molecular compounds in the discovery of a newly invented drug, without much human involvement. Does such AI assistance rise to the level of inventorship?
6 minute read
By Adolfo Pesquera | November 21, 2023
"The documents Hemotek relies upon do not demonstrate active attempts to commercialize any particular invention that would satisfy this definition.," the AAA panel said about Hemotek's breach of contract claim.
5 minute read
By Maria Dinzeo | November 16, 2023
Merlyn Mind, New York-based maker of AI-powered digital assistants for teachers, has found its first general counsel in Google in-house lawyer Scott Pojunas.
2 minute read
Presented by BigVoodoo
The premier educational and networking event for employee benefits brokers and agents.
The Legal Intelligencer honors lawyers leaving a mark on the legal community in Pennsylvania and Delaware.
Consulting Magazine recognizes leaders in technology across three categories Leadership, Client Service and Innovation.
Truly exceptional Bergen County New Jersey Law Firm is growing and seeks strong plaintiff's personal injury Attorney with 5-7 years plaintif...
Shipman is seeking an associate to join our Labor & Employment practice in our Hartford, New Haven, or Stamford office. Candidates shou...
Evergreen Trading is a media investment firm headquartered in NYC. We help brands achieve their goals by leveraging their unwanted assets to...
MELICK & PORTER, LLP PROMOTES CONNECTICUT PARTNERS HOLLY ROGERS, STEVEN BANKS, and ALEXANDER AHRENS